176 related articles for article (PubMed ID: 36455534)
1. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
Meyer HJ; Wienke A; Zamsheva M; Surov A
Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
[TBL] [Abstract][Full Text] [Related]
2. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
Meyer HJ; Wienke A; Surov A
Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
[TBL] [Abstract][Full Text] [Related]
5. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Nutrition; 2021; 91-92():111417. PubMed ID: 34399402
[TBL] [Abstract][Full Text] [Related]
6. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
Surov A; Strobel A; Borggrefe J; Wienke A
Eur Radiol; 2023 Sep; 33(9):6426-6437. PubMed ID: 36929392
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019.
Meyer HJ; Wienke A; Surov A
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):159-168. PubMed ID: 35018725
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
[TBL] [Abstract][Full Text] [Related]
10. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
Wu K; Liu X; Wang Y; Wang X; Li X
Front Public Health; 2022; 10():994351. PubMed ID: 36388369
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer - a Meta-analysis.
Thormann M; Hinnerichs M; Barajas Ordonez F; Saalfeld S; Perrakis A; Croner R; Omari J; Pech M; Zamsheva M; Meyer HJ; Wienke A; Surov A
Acad Radiol; 2023 Aug; 30(8):1552-1561. PubMed ID: 36564257
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
14. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
[TBL] [Abstract][Full Text] [Related]
15. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.
Huiskamp LFJ; Chargi N; Devriese LA; May AM; Huitema ADR; de Bree R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238530
[TBL] [Abstract][Full Text] [Related]
16. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
17. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.
Surov A; Pech M; Gessner D; Mikusko M; Fischer T; Alter M; Wienke A
Clin Nutr; 2021 Oct; 40(10):5298-5310. PubMed ID: 34536638
[TBL] [Abstract][Full Text] [Related]
18. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
[TBL] [Abstract][Full Text] [Related]
19. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
[TBL] [Abstract][Full Text] [Related]
20. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
